An in-depth analysis of all the data on 'Companion Diagnostics market' is covered in a latest published research report added by AllTheResearch. The report is mainly focusing on current market trends influencing the business across assorted regions. Also, provides briefing about market size, share, applications, types and Forecast 2020-2026. The research further focuses on the analysis of key players of the Companion Diagnostics Industry and discusses aspects such as company profiles, production, revenue, sales, product specification, potential, and other essentials. in addition to this report highlights growth strategies embraced by market leaders.
The Companion Diagnostics Market size was valued at US$ 1.8 Bn in 2018 and is expected to grow at a compound annual growth rate (CAGR) of 22% for the forecast period ending 2026 reaching a Market value of US$ 7.1 Bn.
Major Key Players Covered in Report are:
F. Hoffmann-La Roche Ltd. (Switzerland)
Agilent Technologies Inc. (the US)
QIAGEN N.V. (Germany)
Abbott Laboratories Inc. (US)
Almac Group (UK)
Danaher Corporation (US)
Illumina Inc. (US)
bioMérieux SA (France)
Myriad Genetics Inc.
Sysmex Corporation (Japan)
For more information on Companion Diagnostics Market, Get sample pdf at https://www.alltheresearch.com/sample-request/238
The global Companion Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other. The industry Professionals in the global Companion Diagnostics industry will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2026.
Companion Diagnostics Market Segmentation by Type:
By Product (Assays, Kits & Reagents, Software & Services)
By Indication (Cancer, Neurological Diseases, Cardiovascular Diseases, Infectious Diseases, Others)
Companion Diagnostics Market Segmentation by Application:
Pharmaceutical & Biopharmaceutical Companies
Contract Research Organizations
Regional Analysis of Companion Diagnostics Market:
Due to its regional focus, the Companion Diagnostics market is alien to North America, Europe, Asia-Pacific, the Middle East, and Africa as well as Latin America. Major companies are working on distributing their products and services across different regions. In addition, procurements, and associations from some of the leading organizations. All the factors intended to drive the global Companion Diagnostics market are examined in depth.
For more Customization, Connect with us at https://www.alltheresearch.com/customization/238
Unique insights provided by this report also includes the following:
In-depth value chain analysis
Companion Diagnostics Market trends
Covid-19 impact analysis
Raw material supply analysis
Sustainability trends and environmental concerns
Critical Success Factors
The Covid19 pandemic has transformed the market landscape. The market ecosystem has taken a directional shift in the way supply-side of the market is accessed. The report covers the aftermath of the Covid19 catastrophe.
Get the PDF to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies: https://www.alltheresearch.com/impactC19-request/238
Chapters Include in Global Companion Diagnostics Market Research Report 2020 – 2026
Companion Diagnostics Market Overview
Global Economic Impact on Industry
Global Companion Diagnostics Market Competition by Manufacturers
Global Production, Revenue (Value) by Region
Global Supply (Production), Consumption, Export, Import by Regions
Global Production, Revenue (Value), Price Trend by Type
Global Companion Diagnostics Market Analysis by Application
Manufacturing Cost Analysis
Industrial Chain, Sourcing Strategy and Downstream Buyers
Marketing Strategy Analysis, Distributors/Traders
Market Effect Factors Analysis
Global Companion Diagnostics Market Forecast
Buy Exclusive Report at https://www.alltheresearch.com/buy-now/238
Benefits of Purchasing Companion Diagnostics Market Reports:
Analyst Support: Ask a professional analyst to resolve your question before or after purchasing the report.
Customer Satisfaction: Our team of experts assists you with all your research needs and customizes your reports.
Unmatched expertise: Analysts provide in-depth insights into reports.
Guaranteed Quality: Focuses on the quality and accuracy of the report.
For more Details Contact Us:
Contact Name: Rohan
Phone: +1 (407) 768-2028
Home / Healthcare / Companion Diagnostics Market
+1 (407) 768-2028
Log in / Register
Date : Apr 2020
Report ID : 238
Category : Healthcare
Companion diagnostics are a special class of IVDs that provides information that is essential for the safe and effective
use of a corresponding therapeutic product. Drugs and their companion tests refer to each other in their labels. The
FDA approved the first companion diagnostic-related drug, trastuzumab (Herceptin). Trastuzumab is specifically
effective in human epidermal growth factor receptor 2 (HER2) positive cancers, which are associated with poor
outcomes with conventional cytotoxic therapy. Companion diagnostics potentially allow therapy to be given only to
the targeted population which will receive the most benefit, thus improving patient outcomes.
The growth of the companion diagnostics market is primarily driven by the rising prevalence of cancer and growing
trends towards personalized medicine. Cancer is the second leading cause mortalities in 2018, with a continuous rise in
the number of cancer patients across the globe, as per the report published by WHO. Furthermore, it is estimated that 1
out of 6 deaths occurs due to cancer every year across the globe. As per WHO, nearly one-third of the mortalities from
cancer are due to 5 leading behavioural and dietary risk, which includes low fruit and vegetable intake, high body
mass index, lack of physical activity, alcohol consumption, and tobacco use. Tobacco is one of the leading factors for
the rise in the prevalence of cancer and mortalities that accounted for nearly 22% of the global population. The rising
number of cancer patients is the major factor for the growth of the global companion diagnostics market. According
to WHO, in 2018, there were around 18.1 million cases related to cancer and nearly 8.7 million mortalities.
Companion Diagnostics Market Segmentation